# Larry Brown

> Larry Brown, Sc.D., is Executive Vice President of R&D and Chief Scientific Officer at Noveome Biotherapeutics, the Pittsburgh clinical-stage biopharma he joined in 2012. He is leading the translation of ST266, a cell-free secretome of hundreds of proteins harvested from amnion-derived cells, from proof of principle into the clinic. Trained at MIT under Robert Langer and in Judah Folkman's surgical research lab at Children's Hospital Boston, he spent 35-plus years inventing drug-delivery systems at Baxter, Alkermes and biotech startups, accumulating more than 100 publications and a thick stack of patents along the way.

- **Role:** Executive Vice President of R&D and Chief Scientific Officer at Noveome Biotherapeutics, Inc.
- **Organizations:** Noveome Biotherapeutics, Inc., Baxter Healthcare Corporation, Alkermes, Massachusetts Institute of Technology (Deshpande Center collaboration)
- **Nationality:** American
- **Education:** Sc.D. in Biochemistry and Bioengineering (advisor: Prof. Robert Langer), Massachusetts Institute of Technology (MIT), Postdoctoral training, surgical research laboratory of Dr. Judah Folkman, Children's Hospital Boston
- **Known for:** More than 100 publications in pharmaceutical biotechnology, Inventor on key patents in drug delivery and biologics, Led ST266 from proof of principle into clinical-stage development

## Career timeline

- **1980s-2000s** — Holds scientific leadership roles in drug delivery at biotech startups including Alkermes, spanning therapeutic proteins, monoclonal antibodies, nucleic acids and transdermal delivery
- **2000s** — Serves as Vice President of Research and corporate head of drug delivery at Baxter Healthcare Corporation
- **2012** — Joins Noveome Biotherapeutics as EVP of R&D and Chief Scientific Officer
- **2020** — Launches program evaluating ST266 for the severe inflammatory response associated with COVID-19
- **2021** — Publishes preclinical results showing the full ST266 secretome is required for neuroprotective and myelin-protective effects
- **2023** — Noveome receives FDA notification to proceed with Phase 1-2 trial of ST266 in necrotizing enterocolitis in premature infants
- **2024** — Noveome announces issuance of U.S. Patent No. 12,121,546, 'Treatment of Systemic Inflammatory Responses'

## Achievements

- More than 100 publications in pharmaceutical biotechnology
- Inventor on key patents in drug delivery and biologics
- Led ST266 from proof of principle into clinical-stage development
- Secured FDA Orphan Drug and Rare Pediatric Disease designations for ST266 in necrotizing enterocolitis
- Frequent invited speaker at international conferences on drug delivery, diabetes and biotechnology

## Latest updates

- **2024-11** — Noveome announces issuance of U.S. Patent No. 12,121,546, 'Treatment of Systemic Inflammatory Responses'
- **2023-12** — Noveome receives FDA notification to proceed with Phase 1-2 clinical trial of ST266 in necrotizing enterocolitis

## Links

- Website: https://noveome.com
- LinkedIn: http://www.linkedin.com/in/lbrownscd
- Twitter/X: https://twitter.com/NoveomePgh
- Facebook: https://www.facebook.com/noveome/

---

Profile page: https://yespress.io/larry-brown
Published by YesPress — https://yespress.io
Last updated: 2026-06-11